Marc Labs, CSIR-CDRI ink pact for developing coronary, cerebral artery diseases drug
New Delhi: UP based Marc Laboratories and CSIR-CDRI, Lucknow have recently signed an agreement for developing a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.
This may be helpful in treating patient population of coronary and cerebral artery diseases.
The institute has recently obtained the permission to initiate the Phase I clinical trials for the drug.
Arterial thrombosis is an acute complication that develops on the chronic lesions of atherosclerosis leading to heart attack and stroke. Therefore, inhibition of platelet collagen interaction is anticipated to be a promising therapeutic strategy to treat intravascular thrombosis. The compound S-007-867 significantly inhibits collagen mediated platelet activation and subsequently reduces the release of ATP from dense granules and thromboxane A2 via COX1 activation. Thus, it effectively maintains blood flow velocity and delays vascular occlusion (blockage of the blood vessel, usually with a clot) and inhibits thrombogenesis (formation of blood clot) without compromising hemostasis. This drug has less bleeding risk as compared to presently existing therapies for coronary and cerebral artery diseases. In animal experiments, the compound elicited better antithrombotic protection than the standard of care with minimal bleeding tendency.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.